Recent performance and context for United Therapeutics stock

United Therapeutics (UTHR) shares have been relatively stable recently, with modest moves over the past week and month. Longer-term returns over the past 3 months and year have been much stronger.

The stock last closed at US$568.43, giving the company a market value of about US$24.1b. Recent total return figures suggest investors who held for several years have seen very large gains.

For investors, the key takeaway is that short term share price moves have been modest. At the same time, a 14.44% year to date share price return and an 80.55% one year total shareholder return point to momentum that has been building over time.

If United Therapeutics has caught your attention and you are curious about similar opportunities in healthcare, it could be worth checking stocks in our healthcare AI screener as a next step, starting with 34 healthcare AI stocks.

With United Therapeutics posting a 14.4% year-to-date gain and trading below an average analyst price target and an estimated intrinsic value, investors may ask whether there is still a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 11.7% Undervalued

United Therapeutics' most followed valuation narrative points to a fair value of about $644 per share, compared with the recent close at $568.43, framing the current price as a discount to modeled future cash flows.

The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

Curious what kind of revenue path and profit profile are needed for that valuation gap to make sense? The narrative leans on steady top line expansion, resilient margins, and a future earnings multiple that is lower than many peers today. The full story ties those moving parts together in a way that simple P/E snapshots cannot.

The fair value estimate in this narrative is built using a 7.08% discount rate and a detailed path for revenue, earnings and share count. Analysts behind it assume solid but not extreme earnings growth, with profitability staying broadly similar to today and the share count gradually shrinking. The projected future P/E multiple that underpins the price target is slightly lower than the current sector average, which keeps the valuation grounded in relatively conservative earnings expectations rather than aggressive blue sky scenarios.

Result: Fair Value of $644.08 (UNDERVALUED)

However, this hinges on complex clinical and regulatory outcomes, and setbacks for Tyvaso or ralinepag, or tougher drug pricing pressure, could quickly challenge that fair value story.

Another View on United Therapeutics' Valuation

The earlier fair value of $644 comes from a cash flow driven narrative, but the current P/E of 18.7x sits slightly above both peers at 18.3x and the wider US Biotechs group at 16.2x, while still below a fair ratio of 22.9x. That mix of mild premium and potential upside raises a simple question: how much valuation risk are you really comfortable with here?

Next Steps

Given the mixed signals on valuation and sentiment, it makes sense to review the numbers yourself and decide how comfortable you are with the risk and reward balance. To see what optimists are highlighting, take a look at the 3 key rewards.

Looking for more investment ideas?

If you stop with just one stock, you might miss some of the most interesting opportunities out there, so take a few minutes to scan the wider market.

• Hunt for quality at a discount by checking out 1 high quality undervalued stocks that pair solid fundamentals with appealing price tags.
• Lock in potential income streams by reviewing 10 dividend fortresses that combine higher yields with a focus on resilience.
• Seek out under-the-radar opportunities through our screener containing 21 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.